Bellerophon to present at the h.c. wainwright bioconnect 2022 conference

Warren, n.j., jan. 10, 2022 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that naseem amin, m.d., chairman of bellerophon's board of directors, will present a corporate overview at the h.c. wainwright bioconnect 2022 conference, being held virtually january 10-13, 2022.
BLPH Ratings Summary
BLPH Quant Ranking